Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Review

Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment

Authors: Yuze Hua, Sen Yang, Yalu Zhang, Jiayi Li, Mengyi Wang, Palashate Yeerkenbieke, Quan Liao, Qiaofei Liu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Ferroptosis, a novel form of cell death triggered by iron-dependent phospholipid peroxidation, presents significant therapeutic potential across diverse cancer types. Central to cellular metabolism, the metabolic pathways associated with ferroptosis are discernible in both cancerous and immune cells. This review begins by delving into the intricate reciprocal regulation of ferroptosis between cancer and immune cells. It subsequently details how factors within the tumor microenvironment (TME) such as nutrient scarcity, hypoxia, and cellular density modulate ferroptosis sensitivity. We conclude by offering a comprehensive examination of distinct immunophenotypes and environmental and metabolic targets geared towards enhancing ferroptosis responsiveness within the TME. In sum, tailoring precise ferroptosis interventions and combination strategies to suit the unique TME of specific cancers may herald improved patient outcomes.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the Tumor microenvironment. Volume 348. New York, N.Y.): Science; 2015. pp. 74–80. 6230.
4.
Salmon H, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Investig. 2012;122(3):899–910.PubMedPubMedCentralCrossRef
5.
Borst J, et al. CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–47.PubMedCrossRef
6.
7.
Buck MD, et al. Metabolic Instruction of Immunity Cell. 2017;169(4):570–86.PubMed
8.
Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between Metabolism and Cancer Biology. Cell. 2017;168(4):657–69.PubMedCrossRef
9.
Kaymak I, et al. Immunometabolic interplay in the Tumor Microenvironment. Cancer Cell. 2021;39(1):28–37.PubMedCrossRef
10.
Li X, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16(7):425–41.PubMedCrossRef
11.
12.
13.
Hadian K, Stockwell BR. SnapShot: Ferroptosis Cell, 2020. 181(5).
14.
15.
16.
Fang X, et al. Loss of Cardiac Ferritin H facilitates Cardiomyopathy via Slc7a11-Mediated ferroptosis. Circ Res. 2020;127(4):486–501.PubMedCrossRef
17.
Li Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284–99.PubMedPubMedCentralCrossRef
18.
Tonnus W, Linkermann A. The in vivo evidence for regulated necrosis. Immunol Rev. 2017;277(1):128–49.PubMedCrossRef
19.
20.
21.
Guiney SJ, et al. Ferroptosis and cell death mechanisms in Parkinson’s Disease. Neurochem Int. 2017;104:34–48.PubMedCrossRef
22.
23.
Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35(6):830–49.PubMedCrossRef
24.
Gao M et al. Role of Mitochondria in Ferroptosis. Mol Cell, 2019. 73(2).
25.
Doll S, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8.PubMedCrossRef
26.
27.
28.
29.
Zheng J, Conrad M. The metabolic underpinnings of Ferroptosis. Cell Metabol. 2020;32(6):920–37.CrossRef
30.
Zhang J, et al. Targeting the Thioredoxin System for Cancer Therapy. Trends Pharmacol Sci. 2017;38(9):794–808.PubMedCrossRef
31.
Bai L, et al. Thioredoxin-1 rescues MPP/MPTP-Induced ferroptosis by Increasing Glutathione Peroxidase 4. Mol Neurobiol. 2021;58(7):3187–97.PubMedCrossRef
32.
33.
34.
Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–8.PubMedCrossRef
35.
36.
37.
38.
Tang D, et al. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–25.PubMedCrossRef
39.
MacKenzie KD, et al. Bistable expression of CsgD in Salmonella enterica Serovar Typhimurium connects virulence to persistence. Infect Immun. 2015;83(6):2312–26.PubMedPubMedCentralCrossRef
40.
Suthanthiran M, et al. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci USA. 1990;87(9):3343–7.PubMedPubMedCentralCrossRef
41.
Arensman MD, et al. Cystine-glutamate antiporter xCT deficiency suppresses Tumor growth while preserving antitumor immunity. Proc Natl Acad Sci USA. 2019;116(19):9533–42.PubMedPubMedCentralCrossRef
42.
43.
Siska PJ, et al. Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes. J Immunol Methods. 2016;438:51–8.PubMedPubMedCentralCrossRef
44.
Garg SK, et al. Differential dependence on cysteine from transsulfuration versus transport during T cell activation. Antioxid Redox Signal. 2011;15(1):39–47.PubMedPubMedCentralCrossRef
45.
Angelini G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA. 2002;99(3):1491–6.PubMedPubMedCentralCrossRef
46.
Gmünder H, et al. Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell Immunol. 1990;129(1):32–46.PubMedCrossRef
47.
Srivastava MK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77.PubMedCrossRef
48.
van der Windt GJW, et al. Mitochondrial respiratory capacity is a critical regulator of CD8 + T cell memory development. Immunity. 2012;36(1):68–78.PubMedCrossRef
49.
Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol. 2002;2(6):401–9.PubMedCrossRef
50.
Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat Rev Immunol. 2018;18(8):527–35.PubMedCrossRef
51.
52.
Kong R, et al. IFNγ-mediated repression of system xc drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells. J Leukoc Biol. 2021;110(2):301–14.PubMedCrossRef
53.
Habtetsion T et al. Alteration of Tumor metabolism by CD4 + T cells leads to TNF-α-Dependent intensification of oxidative stress and Tumor Cell Death. Cell Metabol, 2018. 28(2).
54.
55.
Michalek RD, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4 + T cell subsets. J Immunol. 2011;186(6):3299–303.PubMedCrossRef
56.
57.
Mougiakakos D, et al. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood. 2011;117(3):857–61.PubMedCrossRef
58.
Drijvers JM, et al. Pharmacologic screening identifies metabolic vulnerabilities of CD8 T cells. Cancer Immunol Res. 2021;9(2):184–99.PubMedCrossRef
59.
Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.PubMedCrossRef
60.
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307.PubMedCrossRef
61.
62.
Ben-Sasson SZ, et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 2013;210(3):491–502.PubMedPubMedCentralCrossRef
63.
Fotaki G, et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology. 2018;7(3):e1395126.PubMedCrossRef
64.
Zhivaki D, et al. Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity. Cell Rep. 2020;33(7):108381.PubMedPubMedCentralCrossRef
65.
Maj T, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in Tumor. Nat Immunol. 2017;18(12):1332–41.PubMedPubMedCentralCrossRef
66.
Piattini F, et al. Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis. European journal of immunology; 2021.
67.
Kapralov AA, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16(3):278–90.PubMedPubMedCentralCrossRef
68.
Mikulska-Ruminska K et al. NO represses the oxygenation of Arachidonoyl PE by 15LOX/PEBP1: mechanism and role in Ferroptosis. Int J Mol Sci, 2021. 22(10).
69.
Zhu H, et al. Asah2 represses the p53-Hmox1 Axis to protect myeloid-derived suppressor cells from Ferroptosis. J Immunol (Baltimore Md: 1950). 2021;206(6):1395–404.CrossRef
70.
Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–20.PubMedCrossRef
71.
72.
Sagiv JY, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562–73.PubMedCrossRef
73.
Christofides A, Kosmopoulos M, Piperi C. Pathophysiological Mech Regulated Cytokines Gliomas Cytokine. 2015;71(2):377–84.
74.
75.
76.
77.
78.
79.
80.
81.
82.
Al-Huseini LMA, et al. Nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) modulates dendritic cell immune function through regulation of p38 MAPK-cAMP-responsive element binding protein/activating transcription factor 1 signaling. J Biol Chem. 2013;288(31):22281–8.PubMedPubMedCentralCrossRef
83.
Williams MA et al. Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter Journal of immunology (Baltimore, Md.: 1950), 2008. 181(7): p. 4545–4559.
84.
Stamenkovic A, et al. Oxidized phosphatidylcholines trigger ferroptosis in cardiomyocytes during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2021;320(3):H1170–h1184.PubMedCrossRef
85.
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–18.PubMedCrossRef
86.
Poznanski SM et al. Metabolic flexibility determines human NK cell functional fate in the Tumor microenvironment. Cell Metabol, 2021. 33(6).
87.
Wu L, et al. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant Prostate cancer and the induction of ferroptosis-related cell death. Cancer Commun (Lond). 2022;42(8):768–83.PubMedCrossRef
88.
Efimova I et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer, 2020. 8(2).
89.
Galluzzi L et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer, 2020. 8(1).
90.
Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–75.PubMedCrossRef
91.
92.
López-Janeiro Á et al. Proteomic analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Cancers, 2021. 13(4).
93.
Obeid M, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14(10):1848–50.PubMedCrossRef
94.
Luo X, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28(6):1971–89.PubMedPubMedCentralCrossRef
95.
Zhou B et al. Ferroptosis is a type of autophagy-dependent cell death. Sem Cancer Biol, 2020. 66.
96.
97.
98.
Dai E, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83.PubMedPubMedCentralCrossRef
99.
100.
101.
Zhao E, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016;17(1):95–103.PubMedCrossRef
102.
Rivadeneira DB, Delgoffe GM. Antitumor T-cell reconditioning: improving metabolic fitness for Optimal Cancer Immunotherapy. Clin Cancer Res. 2018;24(11):2473–81.PubMedPubMedCentralCrossRef
103.
Warburg O. On the origin of cancer cells. Volume 123. New York, N.Y.): Science; 1956. pp. 309–14. 3191.
104.
105.
106.
Song X, et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. Cell Rep. 2021;34(8):108767.PubMedCrossRef
107.
Cham CM, et al. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8 + T cells. Eur J Immunol. 2008;38(9):2438–50.PubMedPubMedCentralCrossRef
108.
109.
Koppula P, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (London England). 2018;38(1):12.
110.
Kamphorst JJ, et al. Human Pancreatic cancer tumors are nutrient poor and Tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75(3):544–53.PubMedPubMedCentralCrossRef
111.
Pan M, et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016;18(10):1090–101.PubMedPubMedCentralCrossRef
112.
113.
114.
Cramer SL, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses Tumor growth. Nat Med. 2017;23(1):120–7.PubMedCrossRef
115.
Daher B, et al. Genetic ablation of the Cystine Transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and Tumor formation via nutrient and oxidative stresses. Cancer Res. 2019;79(15):3877–90.PubMedCrossRef
116.
Meira W et al. A cystine-cysteine intercellular shuttle prevents ferroptosis in xCT pancreatic ductal adenocarcinoma cells. Cancers, 2021. 13(6).
117.
Zhang W, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic Leukaemia. Nat Cell Biol. 2012;14(3):276–86.PubMedPubMedCentralCrossRef
118.
119.
120.
121.
Muir A et al. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife, 2017. 6.
122.
Cassago A, et al. Mitochondrial localization and structure-based phosphate activation mechanism of glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci USA. 2012;109(4):1092–7.PubMedPubMedCentralCrossRef
123.
Jennis M, et al. An african-specific polymorphism in the TP53 gene impairs p53 Tumor suppressor function in a mouse model. Genes Dev. 2016;30(8):918–30.PubMedPubMedCentralCrossRef
124.
Bannai S, Ishii T. A novel function of glutamine in cell culture: utilization of glutamine for the uptake of cystine in human fibroblasts. J Cell Physiol. 1988;137(2):360–6.PubMedCrossRef
125.
126.
CD36 Activity Causes Ferroptosis in Tumor-Infiltrating CD8 T Cells. Cancer discovery., 2021. 11(5): p. OF24.
127.
128.
Ippolito L, et al. Lactate: a metabolic driver in the Tumour Landscape. Trends Biochem Sci. 2019;44(2):153–66.PubMedCrossRef
129.
Manzo T et al. Accumulation of long-chain fatty acids in the Tumor microenvironment drives dysfunction in intrapancreatic CD8 + T cells. J Exp Med, 2020. 217(8).
130.
Ma X et al. CD36-mediated ferroptosis dampens intratumoral CD8 T cell effector function and impairs their antitumor ability. Cell Metabol, 2021.
131.
Zhang Y et al. Enhancing CD8 T cell fatty acid catabolism within a metabolically challenging Tumor Microenvironment increases the efficacy of Melanoma Immunotherapy. Cancer Cell, 2017. 32(3).
132.
133.
Gurusamy D et al. Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell, 2020. 37(6).
134.
Xu S et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells in tumors. Immunity, 2021. 54(7).
135.
Luo X, et al. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12(4):328.PubMedPubMedCentralCrossRef
136.
Liu W, et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and Metastasis in cancer. Nat Commun. 2021;12(1):5103.PubMedPubMedCentralCrossRef
137.
138.
Zhao Y, et al. HCAR1/MCT1 regulates Tumor Ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications. Cell Rep. 2020;33(10):108487.PubMedCrossRef
139.
Pereira ER, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Volume 359. Science (New York, N.Y.),; 2018. pp. 1403–7. 6382.
140.
Brown M, et al. Lymph node blood vessels provide exit routes for metastatic Tumor cell dissemination in mice. Volume 359. New York, N.Y.: Science; 2018. pp. 1408–11. 6382.
141.
Tang Y, et al. Fatty acid activation in carcinogenesis and cancer development: essential roles of long-chain acyl-CoA synthetases. Oncol Lett. 2018;16(2):1390–6.PubMedPubMedCentral
142.
143.
144.
Le Gal K, et al. Antioxidants can increase Melanoma Metastasis in mice. Sci Transl Med. 2015;7(308):308re8.PubMed
145.
146.
Fan Z, et al. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med. 2021;25(21):10197–212.PubMedPubMedCentralCrossRef
147.
Xiong J et al. Hypoxia Enhances HIF1α Transcription Activity by Upregulating KDM4A and Mediating H3K9me3, Thus Inducing Ferroptosis Resistance in Cervical Cancer Cells Stem Cells Int, 2022. 2022: p. 1608806.
148.
Lin Z, et al. Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer. Redox Biol. 2022;52:102312.PubMedPubMedCentralCrossRef
149.
Zou Y, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617.PubMedPubMedCentralCrossRef
150.
151.
152.
153.
154.
Soares MP, Hamza I. Macrophages and Iron Metabolism Immunity. 2016;44(3):492–504.PubMed
155.
156.
Gryzik M et al. Expression and characterization of the ferritin binding domain of Nuclear Receptor Coactivator-4 (NCOA4) Biochimica et biophysica acta. General subjects, 2017. 1861(11 Pt A): p. 2710–2716.
157.
Ajoolabady A, et al. Ferritinophagy and ferroptosis in the management of metabolic Diseases. Trends Endocrinol Metab. 2021;32(7):444–62.PubMedCrossRef
158.
Ni S, et al. Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from ferroptosis. Free Radic Biol Med. 2021;169:271–82.PubMedCrossRef
159.
Taylor M, et al. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron Deficiency in mice. Gastroenterology. 2011;140(7):2044–55.PubMedCrossRef
160.
161.
Poursaitidis I, et al. Oncogene-Selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine. Cell Rep. 2017;18(11):2547–56.PubMedPubMedCentralCrossRef
162.
Yang W-H et al. The Hippo Pathway Effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep, 2019. 28(10).
163.
Yang W-H, et al. A TAZ-ANGPTL4-NOX2 Axis regulates ferroptotic cell death and Chemoresistance in epithelial Ovarian Cancer. Mol cancer Research: MCR. 2020;18(1):79–90.PubMedCrossRef
164.
165.
McGranahan N, Swanton C. Clonal heterogeneity and Tumor Evolution: past, Present, and the future. Cell. 2017;168(4):613–28.PubMedCrossRef
166.
Quezada SA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Investig. 2006;116(7):1935–45.PubMedPubMedCentralCrossRef
167.
Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Volume 313. New York, N.Y.): Science; 2006. pp. 1960–4. 5795.
168.
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.PubMedCrossRef
169.
170.
171.
172.
Tsoi J et al. Multi-stage differentiation defines Melanoma subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent oxidative stress. Cancer Cell, 2018. 33(5).
173.
174.
175.
176.
Duan Q, et al. Turning Cold into Hot: firing up the Tumor Microenvironment. Trends in cancer. 2020;6(7):605–18.PubMedCrossRef
177.
Yang L, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014;5:4436.PubMedCrossRef
178.
Camus M, et al. Coordination of intratumoral immune reaction and human Colorectal cancer recurrence. Cancer Res. 2009;69(6):2685–93.PubMedCrossRef
179.
Mlecnik B, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6(228):228ra37.PubMedCrossRef
180.
Spranger S et al. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell, 2017. 31(5).
181.
182.
van der Woude LL, et al. Migrating into the Tumor: a Roadmap for T cells. Trends Cancer. 2017;3(11):797–808.PubMedCrossRef
183.
Tan SK, et al. Obesity-dependent adipokine chemerin suppresses fatty acid oxidation to Confer Ferroptosis Resistance. Cancer Discov. 2021;11(8):2072–93.PubMedPubMedCentralCrossRef
184.
Zhu J et al. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation Cell Metabolism, 2019. 30(5).
185.
Erdélyi K et al. Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation Proc Natl Acad Sci U S A, 2021. 118(45).
186.
Yang F, et al. Ferroptosis heterogeneity in triple-negative Breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35(1):84–100e8.PubMedCrossRef
187.
Bebber CM et al. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes Nat Commun, 2021. 12(1): p. 2048.
188.
Goji T, et al. Cystine uptake through the cystine/glutamate antiporter xCT triggers Glioblastoma cell death under glucose deprivation. J Biol Chem. 2017;292(48):19721–32.PubMedPubMedCentralCrossRef
189.
190.
Leone RD, et al. Glutamine blockade induces divergent metabolic programs to overcome Tumor immune evasion. Volume 366. New York, N.Y.): Science; 2019. pp. 1013–21. 6468.
191.
Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Volume 321. New York, N.Y.): Science; 2008. pp. 1801–6. 5897.
192.
193.
Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105(48):18782–7.PubMedPubMedCentralCrossRef
194.
Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer. 2017;17(10):577–93.PubMedCrossRef
195.
196.
Mwaikambo BR, et al. Hypoxia up-regulates CD36 expression and function via hypoxia-inducible factor-1- and phosphatidylinositol 3-kinase-dependent mechanisms. J Biol Chem. 2009;284(39):26695–707.PubMedPubMedCentralCrossRef
197.
198.
Liu T, et al. Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance. Neuro Oncol. 2022;24(7):1113–25.PubMedPubMedCentralCrossRef
199.
Fan F, et al. A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. Cancer Res. 2021;81(24):6233–45.PubMedCrossRef
200.
Mao W et al. Statin shapes inflamed Tumor microenvironment and enhances immune checkpoint blockade in non-small cell Lung cancer. JCI Insight, 2022. 7(18).
201.
Cheu JW, et al. Ferroptosis Suppressor Protein 1 inhibition promotes Tumor Ferroptosis and Anti-tumor Immune responses in Liver Cancer. Cell Mol Gastroenterol Hepatol. 2023;16(1):133–59.PubMedPubMedCentralCrossRef
202.
Ruan WY, et al. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma. J Cell Mol Med. 2023;27(13):1820–35.PubMedPubMedCentralCrossRef
203.
Xue Y, et al. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade. Nat Commun. 2023;14(1):4758.PubMedPubMedCentralCrossRef
204.
Li H, et al. Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression. Theranostics. 2023;13(11):3794–813.PubMedPubMedCentralCrossRef
205.
Siegel RL et al. Cancer Statistics, 2021. CA: a cancer journal for clinicians, 2021. 71(1).
206.
Yu W et al. Acquisition of Cisplatin Resistance shifts Head and Neck squamous cell Carcinoma Metabolism toward neutralization of oxidative stress. Cancers, 2020. 12(6).
207.
208.
209.
Wang GX, et al. ∆Np63 inhibits oxidative stress-Induced Cell Death, including ferroptosis, and cooperates with the BCL-2 family to promote Clonogenic Survival. Cell Rep. 2017;21(10):2926–39.PubMedPubMedCentralCrossRef
210.
Wang Y, et al. Frizzled-7 identifies platinum-tolerant Ovarian Cancer cells susceptible to Ferroptosis. Cancer Res. 2021;81(2):384–99.PubMedCrossRef
211.
Okuno S, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human Ovarian cancer cell lines. Br J Cancer. 2003;88(6):951–6.PubMedPubMedCentralCrossRef
212.
Huang Y, et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65(16):7446–54.PubMedCrossRef
213.
Chen HHW, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy Metal-based drugs, 2010. 2010.
214.
Guo J, et al. Ferroptosis: a Novel Anti-tumor Action for Cisplatin. Cancer Res Treat. 2018;50(2):445–60.PubMedCrossRef
215.
Song Z, et al. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci. 2021;276:119399.PubMedCrossRef
216.
Sato M, et al. The ferroptosis inducer erastin irreversibly inhibits system x- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells. Sci Rep. 2018;8(1):968.PubMedPubMedCentralCrossRef
217.
Roh J-L et al. Induction of ferroptotic cell death for overcoming cisplatin resistance of Head and Neck cancer. Cancer Lett, 2016. 381(1).
218.
219.
Chen L, et al. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep. 2015;33(3):1465–74.PubMedCrossRef
220.
Chaudhary N, et al. Lipocalin 2 expression promotes Tumor progression and therapy resistance by inhibiting ferroptosis in Colorectal cancer. Int J Cancer. 2021;149(7):1495–511.PubMedCrossRef
221.
222.
Strobel O, et al. Optimizing the outcomes of Pancreatic cancer Surgery. Nat Rev Clin Oncol. 2019;16(1):11–26.PubMedCrossRef
223.
Tang R, et al. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of Pancreatic cancer. Annals of Translational Medicine. 2020;8(21):1347.PubMedPubMedCentralCrossRef
224.
Lo M, et al. The xc- cystine/glutamate antiporter: a mediator of Pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99(3):464–72.PubMedPubMedCentralCrossRef
225.
226.
227.
228.
Tomita K et al. MiR-7-5p is involved in Ferroptosis Signaling and Radioresistance thru the Generation of ROS in Radioresistant HeLa and SAS cell lines. Int J Mol Sci, 2021. 22(15).
229.
230.
231.
Wan C, et al. Irradiated Tumor cell-derived microparticles mediate Tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020;6(13):eaay9789.PubMedPubMedCentralCrossRef
232.
Lang X, et al. Radiotherapy and Immunotherapy Promote Tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–85.PubMedPubMedCentralCrossRef
233.
Chen P-H, et al. Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. Cell Death Differ. 2020;27(3):1008–22.PubMedCrossRef
234.
Shibata Y, et al. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione Starvation in vitro and in vivo. PLoS ONE. 2019;14(12):e0225931.PubMedPubMedCentralCrossRef
235.
236.
Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–14.PubMedCrossRef
237.
Brown CW et al. Prominin2 drives ferroptosis resistance by stimulating Iron Export. Dev Cell, 2019. 51(5).
238.
239.
Louandre C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133(7):1732–42.PubMedCrossRef
240.
Min Y, et al. Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew Chem Int Ed Engl. 2012;51(27):6742–7.PubMedCrossRef
241.
242.
Xu H, et al. Ferroptosis in the Tumor microenvironment: perspectives for immunotherapy. Trends Mol Med. 2021;27(9):856–67.PubMedCrossRef
243.
244.
McLaughlin M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203–17.PubMedCrossRef
245.
Metadata
Title
Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment
Authors
Yuze Hua
Sen Yang
Yalu Zhang
Jiayi Li
Mengyi Wang
Palashate Yeerkenbieke
Quan Liao
Qiaofei Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-023-02925-5

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors

Research

The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions

Research

CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer

Correction

Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody

Review

Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks

Research

A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits